Literature DB >> 32297483

Update on disease pathogenesis, diagnosis, and management of primary Sjögren's syndrome.

Jing Wang1, Lingyan Zhou2, Bin Liu1.   

Abstract

Primary Sjögren's syndrome (pSS) is a typical multisystem disease, characterized by lymphocytic infiltration of the exocrine glands leading to glandular dysfunction. Multiple systemic manifestations occur in those of serious conditions, with different courses and outcomes. Its pathogenesis is complex, and its diagnosis and management are being constantly updated and improved. We have failed to have much progress in targeted immunotherapy for pSS, and as yet this is still based on empirical treatment. Many studies have tried to define pSS more accurately, to study its pathogenesis, to find effective treatment strategies, opening up new avenues for early diagnosis and precise management of pSS.
© 2020 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  diagnosis; management; pathogenesis; primary Sjögren's syndrome; prognosis

Mesh:

Substances:

Year:  2020        PMID: 32297483     DOI: 10.1111/1756-185X.13839

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  3 in total

1.  Correlations between salivary gland scintigraphy and histopathologic data of salivary glands in patients with primary Sjogren's syndrome.

Authors:  Ji-Won Kim; Roh Jin; Jae Ho Han; Jeong-Hyun Kang; Ju-Yang Jung; Chang-Hee Suh; Young-Sil An; Hyoun-Ah Kim
Journal:  Clin Rheumatol       Date:  2022-06-30       Impact factor: 3.650

Review 2.  Epstein-Barr Virus and Systemic Autoimmune Diseases.

Authors:  Gunnar Houen; Nicole Hartwig Trier
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

3.  Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling.

Authors:  Venkata K Yellepeddi; Kaustubh Parashar; Spencer M Dean; Kevin M Watt; Jonathan E Constance; Olga J Baker
Journal:  Clin Transl Sci       Date:  2020-11-30       Impact factor: 4.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.